Loading...
NPI 1851686331 · Wyomissing, PA · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Anastasia Traband is a retina specialist (ophthalmology) physician provider located in Wyomissing, Pennsylvania. This profile covers 16 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Anastasia Traband |
| Address | 1 Granite Point Dr Ste 100 |
| City | Wyomissing |
| State | PA |
| ZIP | 19610 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | June 13, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $14K |
This provider’s Medicare business is dominant in scale compared with Medicaid: total Medicare revenue is $3.1M versus total Medicaid revenue of $14K, indicating the practice is effectively Medicare-driven rather than Medicaid-driven. The gap in scale means Medicare reimbursement and utilization trends will disproportionately affect overall revenue.
Medicare revenue is highly concentrated in intravitreal drug administration: the precomputed top three Medicare codes account for 82.0% of total Medicare revenue, driven by J0178 (60.3%), J2777 (15.5%), and 67028 (6.2%). Those codes and their descriptions indicate a practice model centered on high-volume anti-VEGF and related intravitreal injection therapy typical of a retina specialty service line.
Medicaid billing is similarly concentrated in a narrow set of retina services: the top three Medicaid codes account for 100.0% of Medicaid revenue, composed of 67028 (42.5%), 92014 (38.8%), and 92134 (18.7%). In-state rank positions for these codes (67028: #60 of 99, 92014: #394 of 861, 92134: #111 of 183) place the provider as a modest, typical participant in Pennsylvania Medicaid for retina procedures and exams.
On Medicare J0178 (aflibercept injection) the provider reports $1.9M revenue and ranks #234 of 3204 providers nationally (93th percentile; notably above typical national volume), marking this clinician as a comparatively high-volume administrator of aflibercept at the national level. 67028 also shows strong national placement (rank #359 of 4255; 92th percentile; notably above typical national volume), reinforcing that intravitreal injections are a core, high-throughput service.
Diagnostic imaging and routine E/M volumes are unusually high relative to national peers: 92134 (retinal imaging) shows $86.8K revenue and ranks #489 of 26868 providers nationally (98th percentile; extreme outlier), and 99213 (established office visit) shows $68.2K revenue and ranks #7077 of 457151 providers nationally (98th percentile; extreme outlier). These placements suggest the practice runs a high-volume combination of imaging and frequent follow-up visits that support the injection workflow.
The provider bills a mix of intravitreal therapeutics beyond aflibercept, indicating clinical use of multiple agents and implants: J2777 (faricimab) generated $485.5K and ranks #647 of 2039 (68th percentile; typical), J2778 (ranibizumab) generated $180K (rank #433 of 1208; 64th percentile; typical), and J7312 (dexamethasone implant) generated $75.2K (rank #56 of 492; 87th percentile; typical). This diversified drug mix points to a retina practice that employs both anti-VEGF agents and steroid implants according to clinical needs rather than a single-product reliance.
The concentration of revenue in a few codes highlights operational sensitivity to shifts in drug utilization, pricing, or reimbursement policy: with the top three Medicare codes accounting for 82.0% of Medicare revenue and the top three Medicaid codes accounting for 100.0% of Medicaid revenue, changes affecting intravitreal drug payment or coding could materially affect overall revenue. Analysts should treat this as a concentrated payor-service exposure rather than a broadly diversified outpatient revenue base.
The provider’s NPI was enumerated on 2011-06-13 (~15 years ago), reflecting an established practice tenure that may support the observed high volumes and national rankings for specific retina services. Longevity combined with the heavy injection-and-imaging mix is consistent with an experienced retina specialist operating a steady, procedure-focused practice.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,720 | $690 | $1.9M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 16,740 | $30 | $485.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,090 | $90 | $193.9K |
| J2778 | Injection, ranibizumab, 0.1 mg | 990 | $180 | $180K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,800 | $30 | $86.8K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 480 | $160 | $75.2K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 960 | $70 | $68.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 810 | $70 | $53.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 510 | $100 | $49.2K |
| J7999 | Compounded drug, not otherwise classified | 590 | $70 | $38.7K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 19 | 140 | 830 | $690 | $865.1K |
| J2778 | 36 | 70 | 1,030 | $190 | $417.1K |
| J2777 | 25 | 100 | 7,950 | $30 | $360.2K |
| 67028 | 26 | 180 | 600 | $90 | $87.5K |
| J7312 | 2 | 10 | 280 | $160 | $50.7K |
| J7999 | 6 | 110 | 100 | $120 | $33.3K |
| 92014 | 110 | 1,570 | 130 | $80 | $21K |
| 99214 | 1,695 | 23,230 | 100 | $80 | $14.5K |
| 92134 | 29 | 1,320 | 60 | $30 | $8.4K |
| 99213 | 203 | 22,370 | 70 | $60 | $7.7K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 160 | $40 | $6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 300 | $20 | $5.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 180 | $20 | $2.6K |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 60 | 100 | 330 | $70 | $85.4K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 394 | 860 | 240 | $40 | $37K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 111 | 180 | 290 | $20 | $24.8K |
Other providers in the same ZIP code as Anastasia Traband, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.